Evidence map›Paper›PMID 34849991›Full record

ArticleThe Journal of antimicrobial chemotherapy2022

BSAC Vanguard Series: The future of infection prevention and control: how COVID is already transforming our approach to antimicrobial resistance.

Andreas Voss

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Andreas VossDepartment of Medical Microbiology, Radboud University Medical Centre, Postbus 6500 HB, Nijmegen, The Netherlands.
Radboud University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID -19 stimulated enormous focus on, and change in, infection prevention and control (IPC), not just in the healthcare sector but also among the general public. While global cooperation and guidance are important, there is also an essential role and benefit from national policies that respect local circumstances and cultural differences. Hospitals will have a new role and data sharing and cooperation between areas such as acute and long-term care will be even more important. Further integration of infection control, microbiology and infectious diseases staff in IPC teams is needed. The digital and AI revolutions have roles to play in how and where patients are seen and diagnosed. The built environment may have longer-term influence on changing the behaviour of health professionals than education and training. One constant is the need for highly trained, flexible and motivated staff in these IPC teams.

Indexed as

COVID-19Cross InfectionAnti-Bacterial AgentsDrug Resistance, BacterialHumansInfection ControlSARS-CoV-2Anti-Bacterial Agents

Identifiers

PMID34849991
PMCPMC8690193
OpenAlexW3217599206

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.